Today, Xylem Inc. (XYL) Stake Raised by Aperio Group LLC

Today, Xylem Inc. (XYL) Stake Raised by Aperio Group LLC
Aperio Group LLC raised its position in Xylem Inc. (NYSE:XYL) by 13.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 154,143 shares of the company’s stock after buying an additional 18,413 shares during the period. Aperio Group LLC owned 0.09% of Xylem worth $8,085,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of XYL. Arizona State Retirement System increased its stake in shares of Xylem by 0.5% in the third quarter. Arizona State Retirement System now owns 44,100 shares of the company’s stock worth $2,313,000 after buying an additional 200 shares during the last quarter. First Trust Advisors LP increased its position in Xylem by 33.4% in the third quarter. First Trust Advisors LP now owns 448,950 shares of the company’s stock valued at $23,547,000 after buying an additional 112,337 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Xylem by 4.5% in the third quarter. Mutual of America Capital Management LLC now owns 21,851 shares of the company’s stock valued at $1,146,000 after buying an additional 934 shares in the last quarter. Rothschild Capital Partners LLC increased its position in Xylem by 24.1% in the third quarter. Rothschild Capital Partners LLC now owns 138,620 shares of the company’s stock valued at $7,271,000 after buying an additional 26,908 shares in the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. increased its position in Xylem by 2.2% in the third quarter. Mizuho Trust & Banking Co. Ltd. now owns 283,304 shares of the company’s stock valued at $14,859,000 after buying an additional 6,003 shares in the last quarter. 84.62% of the stock is owned by hedge funds and other institutional investors.

Xylem Inc. (NYSE:XYL) traded down 0.11% during midday trading on Thursday, reaching $52.86. The company had a trading volume of 1,926,023 shares. Xylem Inc. has a 12 month low of $31.67 and a 12 month high of $54.99. The firm’s 50-day moving average price is $50.31 and its 200 day moving average price is $48.20. The firm has a market capitalization of $9.48 billion, a PE ratio of 29.33 and a beta of 1.18.

Xylem (NYSE:XYL) last released its quarterly earnings data on Tuesday, November 1st. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.01. The company had revenue of $897 million for the quarter, compared to the consensus estimate of $913.53 million. Xylem had a return on equity of 16.38% and a net margin of 8.83%. The company’s quarterly revenue was down .6% compared to the same quarter last year. During the same period last year, the business posted $0.49 EPS. Equities analysts anticipate that Xylem Inc. will post $2.04 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 7th. Stockholders of record on Wednesday, November 9th will be issued a $0.1549 dividend. The ex-dividend date is Monday, November 7th. This represents a $0.62 dividend on an annualized basis and a dividend yield of 1.17%. Xylem’s dividend payout ratio (DPR) is 34.44%.

Several research firms have weighed in on XYL. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $58.00 target price (up from $55.00) on shares of Xylem in a research report on Monday. Northcoast Research began coverage on Xylem in a research report on Thursday, November 17th. They issued a “buy” rating for the company. Stifel Nicolaus lifted their target price on Xylem from $47.00 to $48.00 and gave the company a “hold” rating in a research report on Wednesday, November 2nd. Janney Montgomery Scott raised Xylem from a “neutral” rating to a “buy” rating and lifted their target price for the company from $50.00 to $52.00 in a research report on Wednesday, November 2nd. Finally, Atlantic Securities raised Xylem from a “neutral” rating to an “overweight” rating and set a $54.00 target price for the company in a research report on Monday, August 22nd. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $47.15.

In other news, SVP Claudia S. Toussaint sold 5,300 shares of the stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $47.27, for a total value of $250,531.00. Following the completion of the sale, the senior vice president now owns 44,033 shares in the company, valued at $2,081,439.91. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Colin R. Sabol sold 27,473 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $50.91, for a total value of $1,398,650.43. Following the completion of the sale, the insider now owns 65,530 shares of the company’s stock, valued at approximately $3,336,132.30. The disclosure for this sale can be found here. 0.77% of the stock is owned by insiders.

About Xylem

Related posts

Leave a Comment